N-substituted hydromorphones and the use thereof

Details N-substituted hydromorphones and the use thereof N-substituted hydromorphones and the use thereof

2003-09-24

2004-11-30

Aulakh, Charanjit S. (Department: 1625)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C546S045000, C546S044000

Reexamination Certificate

active

06825205

ABSTRACT:

BACKGROUND OF THE INVENTION
This application claims the priority benefit under 35 U.S.C. § 119(e) of U.S. Provisional Application No. 60/413,254, filed Sep. 25, 2002, the entirety of which is incorporated by reference herein.
1. Field of the Invention
This invention is in the field of medicinal chemistry. In particular, the invention relates to novel N-substituted hydromorphones.
2. Related Art
The primary location of pain control is in the central nervous system (CNS). The three primary classes of opioid receptors, &mgr; (mu), &kgr; (kappa), and &dgr; (delta), are distributed throughout the CNS and the periphery (Foss, J. F.,
The American Journal of Surgery
182 (Suppl to November 2001):19S-26S (2001)). &mgr;, &kgr;, and &dgr; opioid receptors are functionally coupled to pertussis toxin sensitive heterotrimeric G proteins (G
i
) to inhibit adenylyl cyclase activity. Activation of these receptors activates K
+
currents which increases K
+
efflux, i.e., hyperpolarization, thereby reducing voltage-gated Ca
2+
entry. Hyperpolarization of membrane potential by K
+
currents and inhibition of the Ca
2+
influx prevents neurotransmitter release and pain transmission in varying neuronal pathways. However, the principal receptor involved in pain management is the &mgr; opioid receptor (Foss, J. F., ibid). Other consequences of &mgr;-receptor activation include delays in gastrointestinal transit, respiratory depression, miosis, and feelings of well-being (euphoria) (Foss, J. F., ibid).
Opioids, also known as opioid agonists, are a group of drugs that exhibit opium or morphine-like properties, suppress neuronal activity at the above mentioned opioid receptors. The opioids are widely administered for a variety of medical indications but primarily they are employed as moderate to strong analgesics. Opioid compounds have been reported to have a number of side effects, including constipation, dysphoria, respiratory depresession, dizziness, nausea, and pruritus (Yuan, C.-S. et al.,
J. Pharm. Exp. Ther.
300:118-123 (2002)). CNS-mediated side effects include the abuse potential of opioids. Opioids are also effective as a preanesthetic medication and a cough suppressant, and in treating dyspnea, diarrhea and dysentery.
There have been attempts to selectively antagonize opioid-induced side effects via the use of receptor antagonists such as naloxone or nalmephene. However, the success has been limited because these compounds also reverse analgesia and induce opioid withdrawal (Yuan, C.-S. et al.,
J. Pharm. Exp. Ther.
300:118-123 (2002)). Methylnaltrexone, a quaternary derivative of the pure opioid antagonist naltrexone, has been reported to block undesired side effects of opioid pain medications predominantly mediated by peripherally located receptors, while sparing centrally mediated analgesic effect (Yuan, C.-S. et al.,
J. Pharm. Exp. Ther.
300:118-123 (2002)). It has been reported that methylnaltrexone does not cross the blood-brain barrier in humans (Foss, J. F.,
The American Journal of Surgery
182 (Suppl to November 2001):19S-26S (2001)).
There still exists a need in the art to provide efficient analgesia without CNS-mediated side effects.
SUMMARY OF THE INVENTION
The present invention is related to the discovery that N-alkyl substituted hydromorphones represented by Formula I act as &mgr; opioid receptor agonists, and that they do not penetrate the central nervous system (CNS).
The invention is also related to treating, preventing or ameliorating pain, especially chronic pain, in a mammal in need thereof by administering an effective amount of a compound of Formula I as described herein.
The compounds useful in the present invention have not been heretofor reported. Thus, one aspect of the present invention is directed to the novel N-alkyl substituted hydromorphones of Formula I.
Another aspect of the present invention is directed to the novel compounds of Formula I as &mgr; opioid receptor agonists.
Also, an aspect of the present invention is to provide a pharmaceutical composition useful for treating, preventing or ameliorating pain, containing an effective amount of a compound of Formula I in a mixture with one or more pharmaceutically acceptable carriers or diluents.
Additional embodiments and advantages of the invention will be set forth in part in the description that follows, and in part will be obvious from the description, or may be learned by practice of the invention. The embodiments and advantages of the invention will be realized and attained by means of the elements and combinations particularly pointed out in the appended claims.
It is to be understood that both the foregoing general description and the following detailed description are exemplary and explanatory only and are not restrictive of the invention, as claimed.


REFERENCES:
patent: 3536809 (1970-10-01), Applezweig
patent: 3598123 (1971-08-01), Zaffaroni
patent: 3845770 (1974-11-01), Theeuwes et al.
patent: 3916899 (1975-11-01), Theeuwes et al.
patent: 4008719 (1977-02-01), Theeuwes et al.
patent: 5059595 (1991-10-01), Le Grazie
patent: 5073543 (1991-12-01), Marshall et al.
patent: 5120548 (1992-06-01), McClelland et al.
patent: 5354556 (1994-10-01), Sparks et al.
patent: 5591767 (1997-01-01), Mohr et al.
patent: 5639476 (1997-06-01), Oshlack et al.
patent: 5674533 (1997-10-01), Santus et al.
patent: 5698155 (1997-12-01), Grosswald et al.
patent: 5733566 (1998-03-01), Lewis
patent: 6294195 (2001-09-01), Oshlack et al.
Freund, M., and Speyer, E., “Über die Reduktionsprodukte des Thebains,”Ber. 53B:2250-2264, Wiley-VCH Verlag GmbH & Co. (1920).
Rapoport, H., et al., “The Preparation of Some Dihydro Ketones in the Morphine Series by Oppenauer Oxidation,”J. Org. Chem. 15:1103-1107, American Chemical Society (1950).
Small, L., et al., “The Addition of Organomagnesium Halides to Pseudocodeine Types. II. Preparation of Nuclear Alkylated Morphine Derivatives,”J. Am. Chem. Soc. 58:1457-1463, American Chemical Society (1936).
Small, L., et al., “The Addition of Organomagnesium Halides to Pseudocodeine Types. IV. Nuclear-Substituted Morphine Derivatives,”J. Org. Chem. 3:204-232, American Chemical Society (1938).
Database CA 'Online!, Chemical Abstracts Service, Columbus, OH, Accession No. 65:47914, Abstract for Seki, I., “Morphine Alkaloids and Related Compounds. XIV. Preparation of 6-aminohydrophenanthrenes from Hofmann Degradation Products of Morphine Alkaloids,”Chem. Pharm. Bull. 14:453-461 (1966).
International Search Report for International Application No. PCT/US03/29876, mailed on Mar. 2, 2004, The Hague, Netherlands.
Database CA 'Online!, Chemical Abstracts Service, Columbus OH, Accession No. 1921:7163, Abstract for Freund, M., et al., “Reduction products of thebaine,”Ber. 53B:2250-2264, Wiley-VCH Verlag GmbH & Co. (1920).
Baumhaker, Y., and Sarne, Y., “Exposure of NG108-15 Cells to Etorphine Induces an Embedded State of the Opioid Receptor Which Discriminates Between Hydrophilic and Hydrophobic Ligands,”Pharmacology Communications 7:149-155, Overseas Publishers Association and Harwood Academic Publishers (1996).
Brent, P.J., “Behavioural Effect of Pretreatment with Opioid Antagonists and Sigma Binding Site Ligands on the Abnormal Motor Response Produced by the Kappa Opioid Agonist U50,488H in Guinea Pigs,”Neuropharmacology 32:751-760, Pergamon Press (1993).
Buchwald, H., et al., “Long-term, continuous intravenous heparin administration by an implantable infusion pump in ambulatory patients with recurrent venous thrombosis,”Surgery 88:507-516, The C.V. Mosby Company (1980).
During, M.J., et al., “Controlled Release of Dopamine from a Polymeric Brain Implant: In Vivo Characterization,”Ann. Neurol. 25:351-356, Little, Brown and Company (1989).
Foss, J.F., “A Review of the Potential Role of Methylnaltrexone in Opioid Bowel Dysfunction,”Am. J. Surg. 182(Suppl. To Nov. 2001):19S-26S, Excerpta Medica, Inc. (Nov. 2001).
Goodson, J.M., “Dental Applications,” inMedical Applications of Controlled Release, vol. II Applications and Evaluation, Langer, R.S., and Wise, D.L.,

Affiliated with

Also associated with

Rating

N-substituted hydromorphones and the use thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with N-substituted hydromorphones and the use thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and N-substituted hydromorphones and the use thereof will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3356279